Mackenzie Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Mackenzie Financial’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,753	Closed	-$3.19M	–	1034
2019 Q2	$3.19M	Buy	37,753 +34,843	+1,197%	+$3.13M	0.01%	538
2019 Q1	$278K	Sell	2,910 -90	-3%	-$8.07K	﹤0.01%	1122
2018 Q4	$212K	Sell	3,000 -26,275	-90%	-$2.01M	﹤0.01%	1086
2018 Q3	$2.5M	Sell	29,275 -6,005	-17%	-$602K	0.01%	609
2018 Q2	$4.09M	Buy	35,280 +17,000	+93%	+$1.7M	0.01%	491
2018 Q1	$1.48M	Buy	+18,280	New	+$1.41M	﹤0.01%	598

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Mackenzie Financial's ENTA Position: Q3 2019 in Review

Mackenzie Financial sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 37,753 shares — an estimated $3.19M sold.

Mackenzie Financial first reported a position in ENTA in Q1 2018 and held it in 6 quarters. The position peaked at $4.09M in Q2 2018. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Mackenzie Financial reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Mackenzie Financial sold 37,753 Enanta Pharmaceuticals shares in Q3 2019, an estimated $3.19M.
Mackenzie Financial first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Mackenzie Financial's Enanta Pharmaceuticals position peaked at $4.09M in Q2 2018.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Mackenzie Financial's 13F filing for Q3 2019, filed 14 Nov 2019.